Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma

Eun Mi Lee, Sun Young Rha, Jeeyun Lee, Kyong Hwa Park, Jin Hee Ahn

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: The purpose of this prospective multicenter phase II study was to evaluate the efficacy and toxicity of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Methods: Patients with advanced soft tissue or bone sarcoma, previously treated with ifosfamide and anthracycline-based chemotherapies, were treated with docetaxel (35 mg/m 2 over 60 min) and gemcitabine (1,000 mg/m 2 over 100 min) on days 1 and 8 of every 3-week cycle. Results: From September 2008 to August 2010, 30 patients were enrolled; 24 (80.0%) were men and median patient age was 45 years (range 17-70 years). The patients received a total of 136 cycles of therapy (median 4 cycles per patient; range 1-15 cycles). Of these 30 patients, none achieved complete response (CR) and 5 achieved a partial response (PR), making the overall response rate 16.7% (95% CI, 2.5-30.8%). Twelve patients had stable disease (SD), resulting in tumor control (CR or PR or SD) in 17 of 30 patients (56.7%). Median progression-free survival was 2.5 months (range 0.8-15.3 months), and median overall survival was 8.4 months (range 1.4-22.3 months). Grade 3 or 4 neutropenia, thrombocytopenia, and anemia were observed in 17 (56.7%), 13 (43.4%), and 4 (13.3%) patients, respectively. None of these patients, however, had febrile neutropenia or bleeding events, and all non-hematologic toxicities were manageable. Conclusions: The combination of weekly docetaxel and fixed dose rate gemcitabine was tolerable and may be an active regimen in patients with previously treated advanced sarcoma.

Original languageEnglish
Pages (from-to)635-642
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume69
Issue number3
DOIs
Publication statusPublished - 2012 Mar 1

Fingerprint

docetaxel
gemcitabine
Sarcoma
Bone
Tissue
Toxicity
Ifosfamide
Chemotherapy
Anthracyclines
Tumors

Keywords

  • Gemcitabine
  • Sarcoma
  • Survival
  • Weekly docetaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. / Lee, Eun Mi; Rha, Sun Young; Lee, Jeeyun; Park, Kyong Hwa; Ahn, Jin Hee.

In: Cancer Chemotherapy and Pharmacology, Vol. 69, No. 3, 01.03.2012, p. 635-642.

Research output: Contribution to journalArticle

@article{8c8e00eed29647398cebe70f74a9fb27,
title = "Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma",
abstract = "Purpose: The purpose of this prospective multicenter phase II study was to evaluate the efficacy and toxicity of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Methods: Patients with advanced soft tissue or bone sarcoma, previously treated with ifosfamide and anthracycline-based chemotherapies, were treated with docetaxel (35 mg/m 2 over 60 min) and gemcitabine (1,000 mg/m 2 over 100 min) on days 1 and 8 of every 3-week cycle. Results: From September 2008 to August 2010, 30 patients were enrolled; 24 (80.0{\%}) were men and median patient age was 45 years (range 17-70 years). The patients received a total of 136 cycles of therapy (median 4 cycles per patient; range 1-15 cycles). Of these 30 patients, none achieved complete response (CR) and 5 achieved a partial response (PR), making the overall response rate 16.7{\%} (95{\%} CI, 2.5-30.8{\%}). Twelve patients had stable disease (SD), resulting in tumor control (CR or PR or SD) in 17 of 30 patients (56.7{\%}). Median progression-free survival was 2.5 months (range 0.8-15.3 months), and median overall survival was 8.4 months (range 1.4-22.3 months). Grade 3 or 4 neutropenia, thrombocytopenia, and anemia were observed in 17 (56.7{\%}), 13 (43.4{\%}), and 4 (13.3{\%}) patients, respectively. None of these patients, however, had febrile neutropenia or bleeding events, and all non-hematologic toxicities were manageable. Conclusions: The combination of weekly docetaxel and fixed dose rate gemcitabine was tolerable and may be an active regimen in patients with previously treated advanced sarcoma.",
keywords = "Gemcitabine, Sarcoma, Survival, Weekly docetaxel",
author = "Lee, {Eun Mi} and Rha, {Sun Young} and Jeeyun Lee and Park, {Kyong Hwa} and Ahn, {Jin Hee}",
year = "2012",
month = "3",
day = "1",
doi = "10.1007/s00280-011-1742-5",
language = "English",
volume = "69",
pages = "635--642",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma

AU - Lee, Eun Mi

AU - Rha, Sun Young

AU - Lee, Jeeyun

AU - Park, Kyong Hwa

AU - Ahn, Jin Hee

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Purpose: The purpose of this prospective multicenter phase II study was to evaluate the efficacy and toxicity of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Methods: Patients with advanced soft tissue or bone sarcoma, previously treated with ifosfamide and anthracycline-based chemotherapies, were treated with docetaxel (35 mg/m 2 over 60 min) and gemcitabine (1,000 mg/m 2 over 100 min) on days 1 and 8 of every 3-week cycle. Results: From September 2008 to August 2010, 30 patients were enrolled; 24 (80.0%) were men and median patient age was 45 years (range 17-70 years). The patients received a total of 136 cycles of therapy (median 4 cycles per patient; range 1-15 cycles). Of these 30 patients, none achieved complete response (CR) and 5 achieved a partial response (PR), making the overall response rate 16.7% (95% CI, 2.5-30.8%). Twelve patients had stable disease (SD), resulting in tumor control (CR or PR or SD) in 17 of 30 patients (56.7%). Median progression-free survival was 2.5 months (range 0.8-15.3 months), and median overall survival was 8.4 months (range 1.4-22.3 months). Grade 3 or 4 neutropenia, thrombocytopenia, and anemia were observed in 17 (56.7%), 13 (43.4%), and 4 (13.3%) patients, respectively. None of these patients, however, had febrile neutropenia or bleeding events, and all non-hematologic toxicities were manageable. Conclusions: The combination of weekly docetaxel and fixed dose rate gemcitabine was tolerable and may be an active regimen in patients with previously treated advanced sarcoma.

AB - Purpose: The purpose of this prospective multicenter phase II study was to evaluate the efficacy and toxicity of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Methods: Patients with advanced soft tissue or bone sarcoma, previously treated with ifosfamide and anthracycline-based chemotherapies, were treated with docetaxel (35 mg/m 2 over 60 min) and gemcitabine (1,000 mg/m 2 over 100 min) on days 1 and 8 of every 3-week cycle. Results: From September 2008 to August 2010, 30 patients were enrolled; 24 (80.0%) were men and median patient age was 45 years (range 17-70 years). The patients received a total of 136 cycles of therapy (median 4 cycles per patient; range 1-15 cycles). Of these 30 patients, none achieved complete response (CR) and 5 achieved a partial response (PR), making the overall response rate 16.7% (95% CI, 2.5-30.8%). Twelve patients had stable disease (SD), resulting in tumor control (CR or PR or SD) in 17 of 30 patients (56.7%). Median progression-free survival was 2.5 months (range 0.8-15.3 months), and median overall survival was 8.4 months (range 1.4-22.3 months). Grade 3 or 4 neutropenia, thrombocytopenia, and anemia were observed in 17 (56.7%), 13 (43.4%), and 4 (13.3%) patients, respectively. None of these patients, however, had febrile neutropenia or bleeding events, and all non-hematologic toxicities were manageable. Conclusions: The combination of weekly docetaxel and fixed dose rate gemcitabine was tolerable and may be an active regimen in patients with previously treated advanced sarcoma.

KW - Gemcitabine

KW - Sarcoma

KW - Survival

KW - Weekly docetaxel

UR - http://www.scopus.com/inward/record.url?scp=84859760282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859760282&partnerID=8YFLogxK

U2 - 10.1007/s00280-011-1742-5

DO - 10.1007/s00280-011-1742-5

M3 - Article

C2 - 21959979

AN - SCOPUS:84859760282

VL - 69

SP - 635

EP - 642

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -